20/20 Biolabs develops and sells AI-powered blood tests for early cancer and chronic disease detection. Its core product, OneTest for Cancer, screens for multiple cancer types from a single blood draw using protein tumor markers (PTMs) — proteins secreted by tumors — combined with a proprietary machine learning algorithm that incorporates patient factors like age, gender, and smoking history. The company offers two versions: OneTest Standard, priced under $200, which produces a pan-cancer likelihood score, and OneTest Premium, which adds inflammatory and metabolic biomarkers and estimates likelihood for eight specific cancer types. OneTest for Cancer accounts for roughly 88% of revenue. The company sells through direct-to-consumer online channels, over 1,000 retail clinic locations, a partnership with Giant Food supermarkets, and B2B outreach to employers, fire departments, and military veterans. Revenue is primarily direct-pay, as insurance reimbursement is not yet broadly available, though state grants for firefighter cancer screening are a growing driver. The company also sells BioCheck, a field test kit for screening suspicious powders for bioterror agents, and operates CLIAx, a shared CLIA laboratory that allows overseas diagnostics startups to launch tests in the U.S. 20/20 Biolabs recently launched OneTest for Longevity, which measures inflammatory biomarkers and provides dietary guidance, targeting consumers and employer wellness programs. A key near-term catalyst is a 2026 law creating a Medicare reimbursement pathway for multi-cancer early detection tests starting in 2028.